EIR Biopharma

Eye disease therapy developer EIR Biopharma files for a $17 million IPO IPO Overview EIR Biopharma, a preclinical biotech developing in-licensed therapies for eye diseases, filed on Tuesday with the SEC to raise up to $17 million in an initial... Read more